Comparative Effectiveness Research (CER) Policies and the Potential Threat to Pharmaceutical Innovation
Year of publication: |
2013
|
---|---|
Authors: | Vernon, John A. |
Other Persons: | Golec, Joseph H. (contributor) ; Stevens, Stedman (contributor) |
Publisher: |
[2013]: [S.l.] : SSRN |
Subject: | Innovation | Pharmaindustrie | Pharmaceutical industry | Pharmakologie | Pharmacology | EU-Staaten | EU countries | Industrieforschung | Industrial research |
Extent: | 1 Online-Ressource (23 p) |
---|---|
Type of publication: | Book / Working Paper |
Language: | English |
Notes: | Nach Informationen von SSRN wurde die ursprüngliche Fassung des Dokuments February 2, 2010 erstellt |
Other identifiers: | 10.2139/ssrn.1579442 [DOI] |
Classification: | I11 - Analysis of Health Care Markets ; O34 - Intellectual Property Rights: National and International Issues ; I18 - Government Policy; Regulation; Public Health |
Source: | ECONIS - Online Catalogue of the ZBW |
-
The Invention of an Investment Incentive for Pharmaceutical Innovation
Basheer, Shamnad, (2015)
-
Pharmaceutical M&A activity : effects on prices, innovation, and competition
Richman, Barak, (2017)
-
Innovation Incentives in the Pharmaceutical Sector : Re-thinking Competition and Public Policy?
Maier-Rigaud, Frank P., (2021)
- More ...
-
The Case for Less, Not More, US FDA Regulation
Vernon, John A., (2011)
-
Comparative Effectiveness Regulations and Pharmaceutical Innovation
Vernon, John A., (2010)
-
An exploratory study of FDA new drug review times, prescription drug user fee acts, and R&D spending
Vernon, John A., (2009)
- More ...